Michael D Kavanaugh

US Patent:

6548634, Apr 15, 2003

Filed:

Sep 28, 1999

Appl. No.:

09/407687

Inventors:

Marcus Ballinger - Burlingame CA
Michael Kavanaugh - Danville CA

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C07K 700

US Classification:

530326, 530327, 435 72, 435325

Abstract:

Peptidic compositions having FGF receptor affinity, as well as fusion proteins and oligomers of the same, are provided. The subject peptidic compounds are characterized by having little or no homology to naturally occurring bFGF. The subject fusion proteins include the peptidic composition linked to an oligomerization domain, either directly or through a linking group and optionally further include a heparin binding domain. The subject peptidic compositions, fusion proteins and oligomers thereof find use in a variety of applications, including both research and therapeutic applications, in which FGF receptor ligands are employed.

US Patent:

6716626, Apr 6, 2004

Filed:

Nov 16, 2000

Appl. No.:

09/715805

Inventors:

Nobuyuki Itoh - Kyoto, JP
Michael Kavanaugh - Mill Valley CA

Assignee:

Chiron Corporation - Emeryville CA
Kyoto University - Kyoto

International Classification:

C12N 1585

US Classification:

435325, 4352523, 43525411, 4352542, 4353201, 435 691, 536 231, 536 235, 536 243, 530350

Abstract:

This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.

US Patent:

6797695, Sep 28, 2004

Filed:

Oct 20, 2000

Appl. No.:

09/692945

Inventors:

Nobuyuki Itoh - Kyoto, JP
Michael Kavanaugh - Mill Valley CA

Assignee:

Kyoto University - Kyoto
Chiron Corporation - Emeryville CA

International Classification:

A61K 3818

US Classification:

514 12, 530350

Abstract:

This invention relates to human fibroblast growth factor (hFGF-20), and to variants thereof and to polynucleotides encoding FGF-20. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, to methods of treating neuronal degenerative disease such as Parkinsons disease and to methods of treating disorders of the cochlea including those causing hearing loss. The invention also relates to rat fibroblast growth factor (rFGF-20), and to variants thereof and polynucleotides encoding rFGF-20.

US Patent:

7723297, May 25, 2010

Filed:

Apr 17, 2006

Appl. No.:

11/405241

Inventors:

Nobuyuki Itoh - Sakya, JP
Michael Kavanaugh - Mill Valley CA, US

Assignee:

Kyoto University - Sakyo, Kyoto
Novartis Vaccines and Diagnostics, Inc. - Emeryville CA

International Classification:

A61K 38/18
C07K 14/475

US Classification:

514 12, 530350, 530300

Abstract:

This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.

US Patent:

7831962, Nov 9, 2010

Filed:

Jun 3, 2003

Appl. No.:

10/453703

Inventors:

Niloy Banerjee - Fremont CA, US
Bret L. Foreman - San Francisco CA, US
Theodore R. Haining - San Bruno CA, US
Parikshit Bhaduri - Foster City CA, US
Brom Mahbod - San Carlos CA, US
Michael David Kavanaugh - San Francisco CA, US
Dhaval Babulal Shah - Foster City CA, US
Henry S. Willard - San Francisco CA, US
John John E. So - Dublin CA, US

Assignee:

Oracle International Corporation - Redwood Shores CA

International Classification:

G06F 9/44

US Classification:

717126

Abstract:

Techniques for testing subsystems on a platform for a software application are provided. A test application receives instructions for calling platform dependent subsystems directly. The instructions can be designed to fully test the capabilities of the subsystems. Once the instructions are executed, the results of the subsystems can be analyzed for platform certification, performance, reliability, and/or characteristics.

US Patent:

20040054131, Mar 18, 2004

Filed:

Nov 21, 2002

Appl. No.:

10/302100

Inventors:

Marcus Ballinger - Burlingame CA, US
Michael Kavanaugh - Danville CA, US

International Classification:

C07K007/00
C07K016/00
C07K017/00
A61K038/04
C07K005/00

US Classification:

530/330000

Abstract:

Peptidic compositions having FGF receptor affinity, as well as fusion proteins and oligomers of the same, are provided. The subject peptidic compounds are characterized by having little or no homology to naturally occurring bFGF. The subject fusion proteins include the peptidic composition linked to an oligomerization domain, either directly or through a linking group and optionally further include a heparin binding domain. The subject peptidic compositions, fusion proteins and oligomers thereof find use in a variety of applications, including both research and therapeutic applications, in which FGF receptor ligands are employed.

US Patent:

20040185494, Sep 23, 2004

Filed:

Apr 5, 2004

Appl. No.:

10/818140

Inventors:

Nobuyuki Itoh - Sakyo, JP
Michael Kavanaugh - Mill Valley CA, US

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C07K014/50
C12Q001/68
C07H021/04

US Classification:

435/006000, 435/069100, 435/320100, 435/325000, 530/399000, 536/023500

Abstract:

This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.

US Patent:

20050037457, Feb 17, 2005

Filed:

Feb 3, 2004

Appl. No.:

10/771173

Inventors:

Nobuyuki Itoh - Sakyo, JP
Michael Kavanaugh - Mill Valley CA, US

Assignee:

Chiron Corporation - Emeryville CA

International Classification:

C07K014/49

US Classification:

435069100, 435320100, 435325000, 530399000, 536023500

Abstract:

This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.